Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial [PDF]
Journal of Antimicrobial Chemotherapy, 2023 Safety; Antifungal; CandidaemiaSeguridad; Antifúngico; CandidemiaSeguretat; Antifúngic; CandidèmiaBackground Fosmanogepix is a first-in-class antifungal targeting the fungal enzyme Gwt1, with broad-spectrum activity against yeasts and moulds, including ...
Galia Rahav +2 more
exaly +11 more sources
Fosmanogepix: A Review of the First-in-Class Broad Spectrum Agent for the Treatment of Invasive Fungal Infections [PDF]
Journal of Fungi (Basel, Switzerland), 2020 Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix is the N-phosphonooxymethylene prodrug of manogepix, an inhibitor
Karen Joy Shaw, Ashraf S Ibrahim
exaly +7 more sources
A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin [PDF]
Journal of FungiThis mini-review summarizes the clinical outcomes and antifungal susceptibility results, where available, for three new antifungals, including fosmanogepix, ibrexafungerp, and rezafungin, against Candida isolates cultured from patients in clinical trials.
Ana Espinel-Ingroff +1 more
doaj +4 more sources
Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician [PDF]
Infection and Drug Resistance, 2023 Frederic Lamoth1,2 1Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; 2Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University ...
Lamoth F
doaj +3 more sources
Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis [PDF]
mBio, 2022 Cryptococcal Meningitis (CM) is uniformly fatal if not treated, and treatment options are limited. We previously reported on the activity of APX2096, the prodrug of the novel Gwt1 inhibitor APX2039, in a mouse model of CM.
Charles D. Giamberardino +14 more
doaj +4 more sources
Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia [PDF]
Journal of Antimicrobial Chemotherapy, 2023 Abstract Objectives Fosmanogepix (APX001), a first-in-class, intravenous (IV) and oral (PO) antifungal prodrug, is being developed to treat invasive fungal diseases (IFDs). Manogepix (APX001A; active moiety) targets fungal glycosylphosphatidylinositol-anchored cell wall transfer protein 1, inhibiting ...
Oliver A Cornely +2 more
exaly +4 more sources
The Upcoming Antifungal Drugs in Clinical Development for the Treatment of Invasive Candidiasis [PDF]
Infection and Drug ResistanceAnna Zubovskaia, Jose A Vazquez Division of Infectious Diseases, Department of Medicine, Wellstar MCG/Augusta University, Augusta, GA, USACorrespondence: Jose A Vazquez, Division of Infectious Diseases, Department of Medicine, Wellstar MCG/Augusta ...
Zubovskaia A, Vazquez JA
doaj +2 more sources
Successful treatment of a resistant invasive disseminated Fusarium infection in an immunocompetent patient [PDF]
Medical Mycology Case ReportsFusariosis is a severe fungal infection associated with high mortality rates and an increasing incidence. However, its treatment remains challenging due to the frequent resistance of Fusarium species to conventional antifungal therapies.
Frantzeska Frantzeskaki +5 more
doaj +2 more sources
Fosmanogepix: The Novel Anti-Fungal Agent’s Comprehensive Review of in Vitro, in Vivo, and Current Insights From Advancing Clinical Trials [PDF]
CureusFosmanogepix, a prodrug of Manogepix (MGX), is a groundbreaking antifungal agent with broad-spectrum activity against yeasts, including Cryptococcus and Candida, as well as molds. It exhibits effectiveness against drug-resistant strains, such as Candida strains resistant to echinocandins and Aspergillus strains resistant to azoles.
Almajid A +13 more
exaly +4 more sources
Fosmanogepix (APX001) Is Effective in the Treatment of Immunocompromised Mice Infected with Invasive Pulmonary Scedosporiosis or Disseminated Fusariosis [PDF]
Antimicrobial Agents and Chemotherapy, 2020 There are limited treatment options for immunosuppressed patients with lethal invasive fungal infections due to Fusarium and Scedosporium Manogepix (MGX; APX001A) is a novel antifungal that targets the conserved Gwt1 enzyme required for localization of ...
Teclegiorgis Gebremariam +2 more
exaly +3 more sources